GLP-1 agonists have shown promise in HF treatment not only due to their beneficial effects on cardiovascular outcomes but also by managing other organ systems that relate to HF morbidity, including targeting weight loss and glycemic control, which work through the reduction of metabolic complications associated with obesity and HF, MACE, and HF symptoms [63]. Here, GCG is linked to hydrops fetalis.